On April 20, 2026, Nektar Therapeutics reported 52-week results from its REZOLVE-AA study on rezpegaldesleukin for patients with severe alopecia areata, showing 25.8% of patients in the low dose group improved sufficiently compared to 6.7% in the placebo group. The study involved 92 patients, with promising safety and tolerability observed.